Viking Therapeutics, Inc. (VKTX) News
Viking Therapeutics, Inc. (VKTX)
Today's Latest Price: $7.13 USD
Updated Jun 4 6:55pm
Add VKTX to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 214 in Medical - Pharmaceuticals
See all "A" rated Strong Buy stocks
Filter VKTX News Items
VKTX News Results
| Event/Time | Symbol | Company | News Detail | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest VKTX News From Around the Web
Below are the latest news stories about Viking Therapeutics Inc that investors may wish to consider to help them evaluate VKTX as an investment opportunity.
Viking Therapeutics to Participate in Upcoming Investor ConferencesViking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will participate in two upcoming investor conferences. |
Edited Transcript of VKTX earnings conference call or presentation 30-Apr-20 8:30pm GMTQ1 2020 Viking Therapeutics Inc Earnings Call |
7 Biotech Stocks Wall Street Says Will Double or MoreBull market or bear market, one fact remains unwavering: Biotech stocks represent the ultimate risk/reward plays.These investments are inherently volatile in nature. Numerous biotechnology companies have just one or two products delivering revenue, which means any news around new potential treatments has added urgency. That results in bigger price swings. "Pre-revenue" biotech stocks - those with no approved products - are even shakier in nature. These companies are in a race to get a treatment approved before they run out of money for research and trials.Following biotechnology companies isn't like following the rest of the market, either. In many cases, biotech earnings reports aren't a lightning rod for share-price movements. Instead, these stocks tend to ebb and flow on clinical dat... |
Viking Therapeutics Announces 2020 Annual Meeting of Stockholders to be Held as Virtual MeetingSAN DIEGO, May 12, 2020 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced a change to its 2020 Annual Meeting of Stockholders…. |
VKTX: Slight Delay in Enrollment in Phase 2b NASH Trial Due to Ongoing Pandemic…By David Bautz, PhD NASDAQ:VKTX READ THE FULL VKTX RESEARCH REPORT Business Update Slight Delay in Enrollment for VOYAGE Trial Viking Therapeutics, Inc. (NASDAQ:VKTX) is currently conducting the Phase 2b VOYAGE trial of VK2809 in patients with biopsy-confirmed nonalcoholic steatohepatitis (NASH). The randomized, double blind, placebo-controlled trial is expected to enroll approximately 340 |
3 “Strong Buy” Biotech Stocks Trading Under $10Wall Street is experiencing some major déjà vu. The tensions between the U.S. and China flared after President Trump threatened to impose new import tariffs. The difference this time? These tariffs would serve as a punishment for China’s role in the COVID-19 pandemic. In response, stocks posted sharp declines, a rough start to the month of May.The new week of trading could see more of the same. U.S. stock pointed to losses in Monday's trading session as statements made by U.S. Secretary of State Mike Pompeo the day before failed to alleviate trade war fears. Going off of the administration’s earlier statements, Pompeo supported the President’s claim that the virus originated in a Wuhan, China laboratory, adding that the country also stocked up on medical supplies while covering up the e... |
Viking Therapeutics Inc (VKTX) Q1 2020 Earnings Call TranscriptVKTX earnings call for the period ending March 31, 2020. |
Viking Therapeutics Reports First Quarter 2020 Financial Results and Provides Corporate UpdateSAN DIEGO, April 30, 2020 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the first quarter ended… |
Viking Therapeutics to Report Financial Results for First Quarter 2020 on April 30, 2020SAN DIEGO, April 23, 2020 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announced today that the company will release financial results… |
Viking Therapeutics to Participate in 19th Annual Needham Healthcare ConferenceSAN DIEGO, April 7, 2020 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will participate in the Needham &… |
